A study in youth who are missing part of a chromosome is further implicating a suspect gene in schizophrenia. Youth with this genetic chromosomal deletion syndrome already had a nearly 30-fold higher-than-normal risk of schizophrenia, but those who also had one of two common versions of the suspect gene had worse symptoms. They were more prone to cognitive decline, psychosis and frontal lobe tissue loss by late adolescence, when schizophrenia symptoms begin to emerge, found the study, which was funded by the National Institutes of Health's (NIH) National Institute of Mental Health (NIMH) and the National Institute of Child Health and Human Development (NICHD).
The gene version appeared to worsen symptoms of the deletion syndrome by chronically boosting the chemical messenger dopamine to excessive levels in the brain's executive hub, the prefrontal cortex, during development. The study is the first to show the long-term effects of the dopamine-regulating gene in a disorder related to schizophrenia, say Drs. Allan Reiss, Doron Gothelf, Stanford University, and colleagues at the University of Geneva, who report on their findings in the November 2005 issue of Nature Neuroscience.
"It's not that there's a good or bad version of this gene," explained NIMH director Thomas Insel, M.D. "Either version can be an accomplice, via interactions with other genes and environmental factors, in creating a dopamine imbalance that disturbs information processing. In this case, one version conspired with a rare mutation to produce too much dopamine. In other cases, the other version may tip the balance in the opposite direction."
Antipsychotic drugs used to treat schizophrenia work, in part, by correcting a dopamine imbalance in the prefrontal cortex, seat of motivation, learning in response to reward, and working memory functions impaired in schizophrenia. Previous studies have found and the current study confirms that optimal cognitive functioning depends on a "narrow window" of dopamine activity there, note the researchers.
While most people inherit two copies of the gene for the enzyme that breaks down dopamine, one in 4000 children are born with just one copy of the catecho-O-methyltransferase (COMT) gene. The gene is located in the tiny part of chromosome 22 that is partly missing in the 22q11.2 deletion syndrome, also known as the velocardiofacial syndrome. A mutation causes a variable array of problems, including cleft palate, heart defects and cognitive deficits.
Since about 30 percent of people with the chromosomal deletion syndrome also develop schizophrenia or related psychotic disorders compared to only one percent of the general population Reiss and colleagues suspected that people with the syndrome may hold unique clues about how the COMT gene influences development of the mental disorder.
Message posted by: Rashmi Nemade
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...